MARKET

IMCR

IMCR

Immunocore Holdings Plc
NASDAQ
35.34
-0.79
-2.19%
Opening 14:33 09/08 EDT
OPEN
35.83
PREV CLOSE
36.13
HIGH
35.83
LOW
35.04
VOLUME
359.18K
TURNOVER
--
52 WEEK HIGH
40.71
52 WEEK LOW
27.56
MARKET CAP
1.82B
P/E (TTM)
-95.9023
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMCR last week (0831-0904)?
Weekly Report · 1d ago
Weekly Report: what happened at IMCR last week (0824-0828)?
Weekly Report · 08/31 09:19
Weekly Report: what happened at IMCR last week (0817-0821)?
Weekly Report · 08/24 09:19
Immunocore Holdings Price Target Announced at $50.00/Share by JP Morgan
Dow Jones · 08/21 19:17
JP Morgan Reinstates Overweight on Immunocore Holdings, Announces $50 Price Target
Benzinga · 08/21 19:08
Immunocore reinstated with an Overweight at JPMorgan
TipRanks · 08/21 10:30
Is Immunocore Holdings (IMCR) Undervalued After Stronger Revenue And Profitability Results?
Simply Wall St · 08/17 21:25
Weekly Report: what happened at IMCR last week (0810-0814)?
Weekly Report · 08/17 09:19
More
About IMCR
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.

Webull offers Immunocore Holdings PLC - ADR stock information, including NASDAQ: IMCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMCR stock methods without spending real money on the virtual paper trading platform.